Skip to main content
DC 7913Endocrine System

Secondary Conditions for Diabetes Mellitus

9 conditions have documented medical links to Diabetes Mellitus. These may qualify as secondary service-connected disabilities if you can establish a medical nexus.

Evidence Strength:STRONGMODERATEEMERGING
STRONG

Medical Rationale

Diabetes mellitus increases carpal tunnel syndrome (CTS) risk through two synergistic mechanisms. First, diabetic polyneuropathy renders the median nerve more susceptible to compression — the "double crush" phenomenon — because metabolically compromised nerves have reduced tolerance for additional mechanical insult. Hyperglycemia-induced endoneurial edema, sorbitol accumulation through the polyol pathway, and microvascular ischemia of the vasa nervorum create a nerve that is already partially impaired before any external compression. Second, diabetes promotes non-enzymatic glycosylation of the flexor tenosynovium within the carpal tunnel, causing tendon sheath thickening and increased carpal tunnel pressure. CTS prevalence in diabetic populations is 14-30% compared to 3-5% in the general population.

Key Studies

Perkins BA et al. (2002) Diabetes Care (carpal tunnel syndrome in diabetic polyneuropathy); Chammas M et al. (1995) Hand Surg (carpal tunnel syndrome and diabetes — pathophysiology).

Filing Tips

EMG/NCS documenting median nerve entrapment at the wrist with prolonged distal motor and sensory latencies. Document concurrent diabetic peripheral neuropathy (strengthens double-crush argument). Neurology or hand surgery nexus letter addressing the diabetic neuropathy double-crush mechanism and tenosynovial glycosylation. File bilaterally under DC 8515 (median nerve) — rate each hand separately. If surgery is performed, document that diabetes increases surgical complication risk.

STRONG

Medical Rationale

Type 2 diabetes doubles or triples the risk of cardiovascular disease, making coronary artery disease (CAD) the leading cause of death in diabetic patients. Diabetes causes accelerated atherosclerosis through multiple mechanisms: hyperglycemia drives formation of oxidized LDL and AGEs that damage endothelial cells and promote foam cell formation; insulin resistance produces atherogenic dyslipidemia (elevated triglycerides, small dense LDL, low HDL); hyperglycemia impairs endothelial nitric oxide production; platelet hyperaggregability increases thrombotic risk; and inflammatory cytokines (IL-6, TNF-alpha, CRP) from adipose tissue and liver promote plaque instability.

Key Studies

Haffner SM et al. (1998) N Engl J Med (diabetic risk of MI equals prior MI); Buse JB et al. (2007) Circulation; Turner RC et al. (1998) BMJ (UKPDS cardiovascular outcomes); Grundy SM et al. (1999) Circulation (diabetes as CHD risk equivalent).

Filing Tips

Cardiac catheterization or coronary CT angiography documenting CAD; stress test results; EKG changes; history of myocardial infarction with hospital records. Cardiology records documenting treatment (statin therapy, aspirin, beta-blockers, ACE inhibitors) support both the diagnosis and functional severity. This secondary claim is particularly valuable if your primary diabetes is Agent Orange-related (Vietnam veteran), creating a three-tier service connection: Vietnam service → diabetes → coronary artery disease.

STRONG

Medical Rationale

Diabetic nephropathy is the leading cause of end-stage renal disease in the United States, affecting 20–40% of Type 2 diabetic patients. Hyperglycemia causes glomerular hyperfiltration through afferent arteriole dilation, followed by mesangial matrix expansion, glomerular basement membrane thickening, podocyte loss, and progressive glomerulosclerosis (Kimmelstiel-Wilson nodules on renal biopsy). Activation of the renin-angiotensin-aldosterone system (RAAS) by the diabetic kidney compounds intraglomerular hypertension. The clinical progression is: microalbuminuria → macroalbuminuria → decreased GFR → end-stage renal disease requiring dialysis or transplant. The VA rates kidney disease under DC 7101 based on GFR, creatinine levels, and requirement for dialysis.

Key Studies

Viberti GC et al. (1982) Lancet (microalbuminuria and nephropathy); Mogensen CE et al. (1983) BMJ; Adler AI et al. (2003) Kidney Int (UKPDS kidney outcomes); Ritz E & Orth SR (1999) N Engl J Med (nephropathy in Type 2 DM).

Filing Tips

Annual urine albumin-to-creatinine ratio (ACR) and estimated GFR (eGFR) from nephrology or primary care records document disease progression. Renal ultrasound and kidney biopsy (if performed) provide additional support. Request a nexus letter from your nephrologist or endocrinologist. Diabetic nephropathy rated at 30% if creatinine clearance 40–80 ml/min; 60% if 10–40 ml/min; 100% if dialysis required.

STRONG

Medical Rationale

Diabetic retinopathy (DR) is a microangiopathic complication of diabetes resulting from hyperglycemia-induced damage to retinal pericytes and endothelial cells. Loss of pericytes allows capillary microaneurysm formation, hemorrhage, exudate deposition, and macular edema. Neovascularization (proliferative DR) from retinal ischemia and VEGF release risks vitreous hemorrhage and tractional retinal detachment. DR is the leading cause of new blindness in working-age adults in developed countries. Approximately 80% of Type 2 diabetic patients develop some degree of DR after 20 years of disease. The VA rates DR under the Eye section based on visual acuity loss and scotoma.

Key Studies

Klein R et al. (1994) Arch Ophthalmol (Wisconsin Epidemiologic Study); Fong DS et al. (2004) Diabetes Care (ADA retinopathy guidelines); Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group (1991) Ophthalmology; Yau JW et al. (2012) Diabetes Care (global DR meta-analysis).

Filing Tips

Dilated fundus examination by an ophthalmologist documenting DR stage (mild nonproliferative, moderate NPDR, severe NPDR, PDR), presence of diabetic macular edema, and best-corrected visual acuity in each eye. OCT imaging (optical coherence tomography) documenting macular thickness. Fluorescein angiography if neovascularization is present. File for each eye separately. Vision loss rated under DC 6066 (progressive) with separate ratings for near and distant vision impairment.

STRONG

Medical Rationale

Erectile dysfunction affects 35–75% of men with Type 2 diabetes — a 3-fold higher prevalence than age-matched non-diabetic men. Diabetes causes ED through three converging pathways: (1) autonomic neuropathy impairing parasympathetic innervation of penile smooth muscle (cavernous nerve); (2) endothelial dysfunction and accelerated atherosclerosis of the cavernous arteries reducing penile perfusion; and (3) decreased smooth muscle content of the corpus cavernosum reducing compliance and sinusoidal capacity. Advanced glycation end-products crosslink penile structural proteins, reducing elasticity. Diabetic ED is often more refractory to PDE-5 inhibitors than psychogenic or vasculogenic ED because of the combined neurogenic and vascular damage.

Key Studies

Feldman HA et al. (1994) J Urol (MMAS study); Malavige LS & Levy JC (2009) Br J Urol Int (diabetic ED mechanisms); De Berardis G et al. (2002) BMJ; Bacon CG et al. (2002) Ann Intern Med.

Filing Tips

Urology records documenting ED evaluation and treatment. Penile Doppler ultrasound or nocturnal tumescence testing can document vascular and neurogenic etiologies. As with other ED secondary claims, file for SMC-K separately. The nexus letter should address diabetic autonomic neuropathy, cavernous artery atherosclerosis, and endothelial dysfunction as the pathophysiological mechanism.

STRONG

Medical Rationale

This entry documents the clinically and legally important multi-step chain: Agent Orange exposure → Type 2 Diabetes (presumptive) → Diabetic Peripheral Neuropathy (secondary) → Falls/Fractures (tertiary). Diabetic peripheral neuropathy produces the neurological deficits that directly cause falls: loss of protective sensation (inability to detect uneven surfaces), impaired joint proprioception (inability to detect ankle and knee position), distal muscle weakness (foot drop causing toe-catches), and autonomic neuropathy causing orthostatic hypotension. Veterans with Agent Orange diabetes neuropathy have 2–3 times the fall rate of non-diabetic controls and significantly higher hip, vertebral, and wrist fracture rates. Each fracture and its orthopedic residuals (post-traumatic arthritis, malunion, joint replacement) can be separately rated under the musculoskeletal diagnostic codes, creating substantial additive combined disability value.

Key Studies

Schwartz AV et al. (2002) Diabetes Care (DM and hip fracture risk in older adults); Strotmeyer ES et al. (2005) Diabetes Care (neuropathy and fall risk); Cavanagh PR et al. (2007) J Rehabil Res Dev (fall risk in diabetic neuropathy); Gregg EW et al. (2000) Arch Intern Med.

Filing Tips

This is a three-step secondary chain for Vietnam veterans with Agent Orange diabetes: (1) Confirm diabetes is service-connected as an Agent Orange presumptive (38 CFR § 3.309(e)). (2) File DPN as secondary to diabetes with NCS documentation. (3) File each fracture and its residuals as secondary/tertiary to DPN. Hip fracture with resulting total hip arthroplasty can be rated at 100% for one year post-surgery and then at the residual rating. Thorough documentation of the entire causal chain maximizes the additive combined disability rating.

STRONG

Medical Rationale

Diabetic gastroparesis results from autonomic neuropathy affecting the vagus nerve and the enteric nervous system of the stomach. Chronic hyperglycemia produces oxidative stress and advanced glycation end-product (AGE) accumulation in the vagal nerve fibers and interstitial cells of Cajal (ICC) — the pacemaker cells that coordinate gastric peristalsis. As ICC density decreases and vagal efferent function deteriorates, gastric motility is impaired, producing delayed gastric emptying. This causes nausea, vomiting, early satiety, bloating, and paradoxically worsens glycemic control by creating unpredictable nutrient absorption — a vicious cycle. Gastroparesis develops in approximately 30-50% of patients with longstanding diabetes and is strongly associated with peripheral and cardiac autonomic neuropathy.

Key Studies

Camilleri M et al. (2017) Nat Rev Dis Primers (gastroparesis — pathophysiology and management); Bharucha AE et al. (2015) Gastroenterology (epidemiology and natural history of gastroparesis).

Filing Tips

Gastric emptying scintigraphy (4-hour solid-phase study) documenting delayed emptying (>10% retention at 4 hours). Upper endoscopy ruling out mechanical obstruction. Gastroenterology nexus letter linking gastroparesis to service-connected diabetes via vagal autonomic neuropathy. Document concurrent diabetic peripheral neuropathy, as its presence strengthens the argument for autonomic neuropathy. File under DC 7308 (postgastrectomy syndromes) or DC 7319 depending on primary symptoms.

STRONG

Medical Rationale

Hypertension occurs in 75% of patients with Type 2 diabetes. Diabetes causes hypertension through volume expansion (hyperglycemia-driven osmotic fluid retention and RAAS activation promoting sodium reabsorption), endothelial dysfunction reducing nitric oxide bioavailability and increasing vascular resistance, increased sympathetic nervous system activity, and stiffening of large arteries through AGE-mediated crosslinking of vascular collagen. The combination is synergistic — hypertension accelerates diabetic nephropathy, retinopathy, and cardiovascular disease beyond what either condition would cause alone.

Key Studies

Sowers JR et al. (2001) Am Heart J (DM and hypertension mechanisms); UK Prospective Diabetes Study Group (1998) BMJ (UKPDS hypertension data); Ferrannini E & Cushman WC (2012) Lancet (diabetes and hypertension comorbidity).

Filing Tips

Blood pressure records documenting hypertension timeline. A nexus letter from your endocrinologist or internist addressing the RAAS activation and volume expansion mechanism in diabetes-associated hypertension. Hypertension secondary to Agent Orange-presumptive diabetes is a strong, commonly approved secondary claim. Hypertension can then serve as the primary for further secondary claims (kidney disease, heart disease).

STRONG

Medical Rationale

Diabetic peripheral neuropathy (DPN) is the most common complication of Type 2 diabetes, affecting 50% of patients within 25 years of diagnosis. The pathophysiology involves multiple mechanisms: (1) polyol pathway activation — excess glucose is converted to sorbitol by aldose reductase, causing osmotic stress and oxidative damage to Schwann cells; (2) advanced glycation end-product (AGE) formation on neural proteins disrupts axonal transport; (3) oxidative stress from mitochondrial dysfunction; (4) microangiopathy of the vasa nervorum (blood vessels supplying nerves) causing ischemic axonal injury. The result is a length-dependent, symmetrical, distal sensorimotor polyneuropathy with stocking-glove distribution, progressing to autonomic neuropathy. DPN is ratable separately for each affected extremity under the peripheral nerve schedule.

Key Studies

Tesfaye S et al. (2010) Diabetes Care (DPN pathogenesis review); Boulton AJM et al. (2005) Lancet (DPN epidemiology); Pop-Busui R et al. (2017) Diabetes Care (DPN guidelines); Feldman EL et al. (2019) Nat Rev Dis Primers.

Filing Tips

Nerve conduction study (NCS) documenting length-dependent sensorimotor polyneuropathy is the gold standard evidence. The VA rates DPN under the peripheral nerve schedule — upper extremities under DC 8515 (radial), 8712 (ulnar), 8516 (median); lower extremities under DC 8520 (sciatic), 8521 (common peroneal), 8522 (tibial). File for each affected extremity separately. This is a high-value secondary claim given the additive combined rating benefit. HbA1c history correlating with neuropathy onset strengthens the temporal nexus.

← Back to Diabetes Mellitus rating criteria

Find All Secondary Conditions for Your Situation

AIDEN can analyze your complete medical history and identify secondary conditions specific to your case, including connections that may not appear in standard databases.

Discover Your Secondary Conditions